That would be the case if the board had a short term view and...

That would be the case if the board had a short term view and simply wanted to sell out for as much as they can in the next few months. I don't think this is the boards attention . Indeed I think SI would be horrified at the thought, $10 would be a insult but would a offer of that value be excepted by the big end of town?

Post P3 readout represents a period that MSB will be very vulnerable to what SI would consider as a hostile takeover bid, while the market is arguing and trying to set a value be it at $4 or $8 a offer around $12 could well be excepted . Not a great outcome when you look at ecoool's great posts.

SI has spoken about multiple potential partners and that they have discussed what a confirmatory global P3 CHF trial would look like. This is not something that would be discussed openly with any one so I have no doubt that SI has a short list. And now considering how close the CHF results are most parties including MSB will be waiting for them before finale contracts are negotiated and approved by the boards. This will take some time unless they have already made agreements for various P3 outcomes.

I believe this is why we are been informed to expect results later in the year not in Feb or March that many may have anticipated.

2020 Biotech Showcase
Has this presentation been the most successful yet?Seems that we may have raised the eyebrows of our American friends and voted no. 1 The SP would suggest this. Are we finally going to see the value of the American listing? I agree with ecoool's past post and he posted various charts to proof that Australia SP tends to set the value of the Meso. Is there any reason that this can't be reversed?
We are about to find out in the coming weeks
Good luck all.